Sign in
Taking people in United StatesPhase 2

Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

Key facts

Who runs it
University Medical Center Groningen
Where
Basking Ridge, Columbus, Commack, Durham, Grand Rapids, Harrison, Las Vegas, Miami Beach, Middletown, Montvale, New York, Oklahoma City, Omaha, Orange, Providence, Raleigh, Sioux Falls, Springfield, Sylvania, Traverse City, and Uniondale, United StatesSee the 21 sitesAlso in 4 other countries, 26 sites
Status
Recruiting
Phase
Phase 2
People taking part
157 people, planned
Started
1 Jan 2021
Expected to end
1 Jan 2029
Type of study
Interventional
Treatments tested
  • Radiotherapy combined with cisplatin
  • Cisplatin
Record updated
1 August 2023

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Histological confirmed primary SCC of the vulva
  • T1 tumor, not encroaching urethra/vagina/anus
  • Depth of invasion > 1mm
  • Tumor diameter < 4cm
  • Unifocal tumor
  • No enlarged (>1.5cm) or suspicious inguinofemoral lymph nodes at imaging (CT/MRI/ultrasound)
  • Possibility to obtain informed consent
  • Metastatic sentinel lymph node; size of metastasis > 2mm and / or extracapsular extension, or
  • Metastatic sentinel lymph node: more than 1 SN with metastasis ≤ 2mm
  • Patients are able to understand requirements of study, provide written informed consent and comply with the study and follow-up procedures
  • Adequate bone marrow, renal and liver function:; Absolute neutrophil count ≥ 1.5 x 109 /L; Platelet count ≥ 100 x 109 /L; Creatinine clearance ≥ 40 ml/min measured by the Cockroft Gault formula; Total bilirubin < 1.25 x ULN Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN
  • Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale (Appendix A)
  • Age 18 years or older
  • Life expectancy of ≥ 12 weeks
  • Written informed consent

Who cannot take part

  • History of any infection requiring hospitalization or antibiotics within 2 weeks before enrollment
  • Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids
  • Unstable angina, myocardial infarction, cerebrovascular accident, > Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure (see Appendix B) within 6 months before enrollment
  • History of pelvic radiotherapy
  • Inoperable tumors and tumors > 4cm
  • Multifocal tumors
  • Tumors with other pathology than squamous cell carcinoma
  • Patients with enlarged / suspicious lymph nodes which are proven metastatic after fine needle aspiration cytology
  • No other carcinomas, other than basal cell carcinomas, within last 5 years
  • Pregnant female or nursing mother
  • Desire to become pregnant

This trial is currently available in United States.

Also in 4 other countries, 26 sites

  • Memorial Sloan Kettering Basking RidgeBasking Ridge, United StatesContact: Mario Leitao (principal investigator)Taking people
  • Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Christa Nagel (principal investigator)Taking people
  • Memorial Sloan Kettering CommackCommack, United StatesContact: Mario Leitao (principal investigator)Taking people
  • Duke University Medical CenterDurham, United StatesContact: Diandra Ayala-Peacock (principal investigator)Taking people
  • Spectrum Health at Butterworth CampusGrand Rapids, United StatesContact: Kathleen Yost (principal investigator)Taking people
  • Memorial Sloan Kettering WestchesterHarrison, United StatesContact: Mario Leitao (principal investigator)Taking people
  • Women's Cancer Center of NevadaLas Vegas, United StatesContact: Nicola Spirtos (principal investigator)Taking people
  • Mount Sinai Medical CenterMiami Beach, United StatesContact: Brian Slomovitz (principal investigator)Taking people
  • Memorial Sloan Kettering MonmouthMiddletown, United StatesContact: Mario Leitao (principal investigator)Taking people
  • Memorial Sloan Kettering BergenMontvale, United StatesContact: Mario Leitao (principal investigator)Taking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Mario Leitao (principal investigator)Taking people
  • University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Laura Holman (principal investigator)Taking people
  • Nebraska Methodist HospitalOmaha, United StatesContact: Brent Tierney (principal investigator)Taking people
  • UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, United StatesContact: Krishnansu Tewari (principal investigator)Taking people
  • Women and Infants HospitalProvidence, United StatesContact: Paul DiSilvestro (principal investigator)Taking people
  • Duke Women's Cancer Care RaleighRaleigh, United StatesContact: Daindra Ayala-Peacock (principal investigator)Taking people
  • Avera Cancer InstituteSioux Falls, United StatesContact: David Starks (principal investigator)Taking people
  • Baystate Medical CenterSpringfield, United StatesContact: Tashanna Myers (principal investigator)Taking people
  • ProMedica Flower HospitalSylvania, United StatesContact: Adam Walter (principal investigator)Taking people
  • Munson Medical CenterTraverse City, United StatesContact: Kathleen Yost (principal investigator)Taking people
  • Memorial Sloan Kettering NassauUniondale, United StatesContact: Mario Leitao (principal investigator)Taking people

About the trial

What the trial wants to find out

Vulvar cancer patients with SN-metastasis > 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.

The group in the trial

  • ChemoradiationTreatment being tested

    Inguinofemoral radiotherapy (48-50 Gy in 1.8 Gy daily fractions, with a boost dose to the involved inguinal site for a total equivalent dose of 56 Gy over 5-6 weeks, preferably with simultaneous integrated boost technique) combined with weekly cisplatin 40 mg/m2 intravenously on days 1, 8, 15, 22 and 29

    Treatment: Radiotherapy combined with cisplatin and Cisplatin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III, a Prospective Phase II Treatment Trial
Publications
Record updated
1 August 2023